Macrocure is a biotechnology company founded in 2008 with a focus on developing and commercializing advanced cell therapy products. The company's primary area of interest lies in wound care, utilizing activated white blood cells obtained from young healthy donor blood. Macrocure received a significant $35.00M Series A investment on 14 May 2012 from Jerusalem Global Ventures. The company operates within the Biotechnology, Health Care, and Pharmaceutical industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $35.00M | 1 |
|
14 May 2012 |
| Venture Round | $13.00M | 3 |
|
01 Apr 2011 |
No recent news or press coverage available for Macrocure.
We care about your data, and we'd love to use cookies make your experience better.
